2024-06-012025-05-312025-05-31false08476991Alan Patient & Co Limited2025-12-09falseiso4217:GBPxbrli:pure084769912024-05-31084769912025-05-31084769912024-06-012025-05-31084769912023-05-31084769912024-05-31084769912023-06-012024-05-3108476991bus:SmallEntities2024-06-012025-05-3108476991bus:AuditExempt-NoAccountantsReport2024-06-012025-05-3108476991bus:FullAccounts2024-06-012025-05-3108476991bus:PrivateLimitedCompanyLtd2024-06-012025-05-3108476991core:WithinOneYear2025-05-3108476991core:AfterOneYear2025-05-3108476991core:WithinOneYear2024-05-3108476991core:AfterOneYear2024-05-3108476991core:ShareCapital2025-05-3108476991core:SharePremium2025-05-3108476991core:RevaluationReserve2025-05-3108476991core:OtherReservesSubtotal2025-05-3108476991core:RetainedEarningsAccumulatedLosses2025-05-3108476991core:ShareCapital2024-05-3108476991core:SharePremium2024-05-3108476991core:RevaluationReserve2024-05-3108476991core:OtherReservesSubtotal2024-05-3108476991core:RetainedEarningsAccumulatedLosses2024-05-3108476991core:LandBuildings2025-05-3108476991core:PlantMachinery2025-05-3108476991core:Vehicles2025-05-3108476991core:FurnitureFittings2025-05-3108476991core:OfficeEquipment2025-05-3108476991core:NetGoodwill2025-05-3108476991core:IntangibleAssetsOtherThanGoodwill2025-05-3108476991core:ListedExchangeTraded2025-05-3108476991core:UnlistedNon-exchangeTraded2025-05-3108476991core:LandBuildings2024-05-3108476991core:PlantMachinery2024-05-3108476991core:Vehicles2024-05-3108476991core:FurnitureFittings2024-05-3108476991core:OfficeEquipment2024-05-3108476991core:NetGoodwill2024-05-3108476991core:IntangibleAssetsOtherThanGoodwill2024-05-3108476991core:ListedExchangeTraded2024-05-3108476991core:UnlistedNon-exchangeTraded2024-05-3108476991core:LandBuildings2024-06-012025-05-3108476991core:PlantMachinery2024-06-012025-05-3108476991core:Vehicles2024-06-012025-05-3108476991core:FurnitureFittings2024-06-012025-05-3108476991core:OfficeEquipment2024-06-012025-05-3108476991core:NetGoodwill2024-06-012025-05-3108476991core:IntangibleAssetsOtherThanGoodwill2024-06-012025-05-3108476991core:ListedExchangeTraded2024-06-012025-05-3108476991core:UnlistedNon-exchangeTraded2024-06-012025-05-3108476991core:MoreThanFiveYears2024-06-012025-05-3108476991core:Non-currentFinancialInstruments2025-05-3108476991core:Non-currentFinancialInstruments2024-05-3108476991dpl:CostSales2024-06-012025-05-3108476991dpl:DistributionCosts2024-06-012025-05-3108476991core:LandBuildings2024-06-012025-05-3108476991core:PlantMachinery2024-06-012025-05-3108476991core:Vehicles2024-06-012025-05-3108476991core:FurnitureFittings2024-06-012025-05-3108476991core:OfficeEquipment2024-06-012025-05-3108476991dpl:AdministrativeExpenses2024-06-012025-05-3108476991core:NetGoodwill2024-06-012025-05-3108476991core:IntangibleAssetsOtherThanGoodwill2024-06-012025-05-3108476991dpl:GroupUndertakings2024-06-012025-05-3108476991dpl:ParticipatingInterests2024-06-012025-05-3108476991dpl:GroupUndertakingscore:ListedExchangeTraded2024-06-012025-05-3108476991core:ListedExchangeTraded2024-06-012025-05-3108476991dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-06-012025-05-3108476991core:UnlistedNon-exchangeTraded2024-06-012025-05-3108476991dpl:CostSales2023-06-012024-05-3108476991dpl:DistributionCosts2023-06-012024-05-3108476991core:LandBuildings2023-06-012024-05-3108476991core:PlantMachinery2023-06-012024-05-3108476991core:Vehicles2023-06-012024-05-3108476991core:FurnitureFittings2023-06-012024-05-3108476991core:OfficeEquipment2023-06-012024-05-3108476991dpl:AdministrativeExpenses2023-06-012024-05-3108476991core:NetGoodwill2023-06-012024-05-3108476991core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3108476991dpl:GroupUndertakings2023-06-012024-05-3108476991dpl:ParticipatingInterests2023-06-012024-05-3108476991dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3108476991core:ListedExchangeTraded2023-06-012024-05-3108476991dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3108476991core:UnlistedNon-exchangeTraded2023-06-012024-05-3108476991core:NetGoodwill2025-05-3108476991core:IntangibleAssetsOtherThanGoodwill2025-05-3108476991core:LandBuildings2025-05-3108476991core:PlantMachinery2025-05-3108476991core:Vehicles2025-05-3108476991core:FurnitureFittings2025-05-3108476991core:OfficeEquipment2025-05-3108476991core:AfterOneYear2025-05-3108476991core:WithinOneYear2025-05-3108476991core:ListedExchangeTraded2025-05-3108476991core:UnlistedNon-exchangeTraded2025-05-3108476991core:ShareCapital2025-05-3108476991core:SharePremium2025-05-3108476991core:RevaluationReserve2025-05-3108476991core:OtherReservesSubtotal2025-05-3108476991core:RetainedEarningsAccumulatedLosses2025-05-3108476991core:NetGoodwill2024-05-3108476991core:IntangibleAssetsOtherThanGoodwill2024-05-3108476991core:LandBuildings2024-05-3108476991core:PlantMachinery2024-05-3108476991core:Vehicles2024-05-3108476991core:FurnitureFittings2024-05-3108476991core:OfficeEquipment2024-05-3108476991core:AfterOneYear2024-05-3108476991core:WithinOneYear2024-05-3108476991core:ListedExchangeTraded2024-05-3108476991core:UnlistedNon-exchangeTraded2024-05-3108476991core:ShareCapital2024-05-3108476991core:SharePremium2024-05-3108476991core:RevaluationReserve2024-05-3108476991core:OtherReservesSubtotal2024-05-3108476991core:RetainedEarningsAccumulatedLosses2024-05-3108476991core:NetGoodwill2023-05-3108476991core:IntangibleAssetsOtherThanGoodwill2023-05-3108476991core:LandBuildings2023-05-3108476991core:PlantMachinery2023-05-3108476991core:Vehicles2023-05-3108476991core:FurnitureFittings2023-05-3108476991core:OfficeEquipment2023-05-3108476991core:AfterOneYear2023-05-3108476991core:WithinOneYear2023-05-3108476991core:ListedExchangeTraded2023-05-3108476991core:UnlistedNon-exchangeTraded2023-05-3108476991core:ShareCapital2023-05-3108476991core:SharePremium2023-05-3108476991core:RevaluationReserve2023-05-3108476991core:OtherReservesSubtotal2023-05-3108476991core:RetainedEarningsAccumulatedLosses2023-05-3108476991core:AfterOneYear2024-06-012025-05-3108476991core:WithinOneYear2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:CostValuation2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-06-012025-05-3108476991core:Non-currentFinancialInstrumentscore:CostValuation2025-05-3108476991core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-05-3108476991core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3108476991core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3108476991core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3108476991core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3108476991core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3108476991core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3108476991core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3108476991core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3108476991core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3108476991bus:Director12024-06-012025-05-3108476991bus:Director22024-06-012025-05-3108476991core:FurnitureFittingsToolsEquipment2024-05-3108476991core:FurnitureFittingsToolsEquipment2024-06-012025-05-3108476991core:FurnitureFittingsToolsEquipment2025-05-31

Alan Patient & Co Limited

Registered Number
08476991
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2025

Alan Patient & Co Limited
Company Information
for the year from 1 June 2024 to 31 May 2025

Directors

Alan Stephen Patient
Larissa Patient

Registered Address

42 High Street, Wanstead
London
E11 2RJ

Registered Number

08476991 (England and Wales)
Alan Patient & Co Limited
Balance Sheet as at
31 May 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets3140,000157,500
Tangible assets4101,356111,328
241,356268,828
Current assets
Debtors5,61,120,062999,608
Cash at bank and on hand62,82442,108
1,182,8861,041,716
Creditors amounts falling due within one year7(410,129)(362,479)
Net current assets (liabilities)772,757679,237
Total assets less current liabilities1,014,113948,065
Creditors amounts falling due after one year8(456,832)(488,480)
Provisions for liabilities9(28,839)(31,657)
Net assets528,442427,928
Capital and reserves
Called up share capital115115
Profit and loss account528,327427,813
Shareholders' funds528,442427,928
The financial statements were approved and authorised for issue by the Board of Directors on 9 December 2025, and are signed on its behalf by:
Alan Stephen Patient
Director
Registered Company No. 08476991
Alan Patient & Co Limited
Notes to the Financial Statements
for the year ended 31 May 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover comprises revenue earned from the rendering of services.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Fixtures and fittings5
Office Equipment3
2.Average number of employees

20252024
Average number of employees during the year76
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 June 24350,000350,000
At 31 May 25350,000350,000
Amortisation and impairment
At 01 June 24192,500192,500
Charge for year17,50017,500
At 31 May 25210,000210,000
Net book value
At 31 May 25140,000140,000
At 31 May 24157,500157,500
4.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 June 24153,66017,814171,474
Additions16,4259,11625,541
At 31 May 25170,08526,930197,015
Depreciation and impairment
At 01 June 2442,78717,35960,146
Charge for year32,2003,31335,513
At 31 May 2574,98720,67295,659
Net book value
At 31 May 2595,0986,258101,356
At 31 May 24110,873455111,328
5.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables116,428148,092
Other debtors84,13922,416
Prepayments and accrued income1,9954,100
Total202,562174,608
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
6.Debtors: amounts due after one year

2025

2024

££
Other debtors917,500825,000
Total917,500825,000
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables24,30643,806
Bank borrowings and overdrafts111,517109,232
Amounts owed to related parties7,6861,925
Taxation and social security110,34570,606
Other creditors2,4764,886
Accrued liabilities and deferred income153,799132,024
Total410,129362,479
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
8.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts179,332248,480
Amounts owed to related parties277,500240,000
Total456,832488,480
9.Provisions for liabilities

2025

2024

££
Net deferred tax liability (asset)25,33927,832
Other provisions3,5003,825
Total28,83931,657